Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SCNI logo SCNI
Upturn stock ratingUpturn stock rating
SCNI logo

Scinai Immunotherapeutics Ltd (SCNI)

Upturn stock ratingUpturn stock rating
$2.28
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: SCNI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $700

1 Year Target Price $700

Analysts Price Target For last 52 week
$700Target price
Low$1.9
Current$2.28
high$5.89

Analysis of Past Performance

Type Stock
Historic Profit -31.06%
Avg. Invested days 35
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 2.28M USD
Price to earnings Ratio -
1Y Target Price 700
Price to earnings Ratio -
1Y Target Price 700
Volume (30-day avg) 1
Beta 2.09
52 Weeks Range 1.90 - 5.89
Updated Date 06/30/2025
52 Weeks Range 1.90 - 5.89
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 728.88%
Operating Margin (TTM) -1098.54%

Management Effectiveness

Return on Assets (TTM) -34.92%
Return on Equity (TTM) 177.37%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 8028815
Price to Sales(TTM) 3.46
Enterprise Value 8028815
Price to Sales(TTM) 3.46
Enterprise Value to Revenue 12.2
Enterprise Value to EBITDA 1.02
Shares Outstanding 999919
Shares Floating 2442673465
Shares Outstanding 999919
Shares Floating 2442673465
Percent Insiders 18.22
Percent Institutions 26.55

Analyst Ratings

Rating 1
Target Price 700
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Scinai Immunotherapeutics Ltd

stock logo

Company Overview

overview logo History and Background

Scinai Immunotherapeutics Ltd. (SCNI) is a biopharmaceutical company primarily focused on developing and commercializing innovative biological products and platforms. While historical details are limited in readily available public sources, the company's focus has been on building a diverse portfolio of therapeutic candidates, including those targeting autoimmune diseases and cancer.

business area logo Core Business Areas

  • Development and Commercialization of Immunotherapies: Focuses on research, development, and commercialization of innovative immunotherapeutic products to treat diseases with unmet needs. This involves pre-clinical, clinical trials, and potential manufacturing.
  • Partnering and Licensing: Collaborating with other pharmaceutical and biotech companies through licensing agreements or partnerships to expand product reach and development capabilities.

leadership logo Leadership and Structure

Information on specific individuals is limited, but the company likely operates with a CEO, CFO, CSO, and a board of directors overseeing strategy and operations. The organizational structure likely includes departments for research and development, clinical trials, regulatory affairs, and business development.

Top Products and Market Share

overview logo Key Offerings

  • IL-18 Binding Protein (IL-18BP) Platform: IL-18BP's antagonists are thought to be effective and have shown potential in treating autoimmune and inflammatory conditions. Market share data is not readily available. Competitors include companies developing similar interleukin inhibitors and other autoimmune treatments. Potential competitors are major pharmaceutical companies in the autoimmune space.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The immunotherapy market is experiencing significant growth due to advancements in understanding the immune system and developing targeted therapies.

Positioning

Scinai Immunotherapeutics Ltd aims to carve a niche by focusing on developing novel immunotherapies. They are positioning themsleves to capitalize on unmet needs. Competitive advantages would rely on the efficacy and uniqueness of the technology platform and speed to market.

Total Addressable Market (TAM)

The global immunotherapy market is projected to reach hundreds of billions of USD. Scinai Immunotherapeutics Ltd's position relative to this TAM is currently small, but potential products could increase its portion of the TAM with effective development and comercialization.

Upturn SWOT Analysis

Strengths

  • Proprietary IL-18BP technology platform
  • Focus on immunotherapeutic development
  • Potential for partnerships and licensing agreements

Weaknesses

  • Limited financial resources
  • Dependence on successful clinical trials
  • Smaller size compared to major pharmaceutical companies
  • Limited revenue

Opportunities

  • Growing demand for immunotherapies
  • Potential for breakthrough treatments
  • Strategic partnerships to expand reach and funding
  • Increasing prevalence of autoimmune diseases

Threats

  • Competition from larger pharmaceutical companies
  • Clinical trial failures
  • Regulatory hurdles and approval delays
  • Patent expirations

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • JNJ
  • MRK

Competitive Landscape

Scinai Immunotherapeutics Ltd faces intense competition from larger pharmaceutical companies with greater resources and established market presence. Scinai Immunotherapeutics Ltd advantages would rely on the innovation and efficacy of its technology and it niche focus. Scinai Immunotherapeutics Ltd disadvantages include the limited amount of funding and resources to compete.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is largely dependent on its technological advancements, collaborations, and clinical trial milestones.

Future Projections: Future projections are speculative and based on the success of its clinical trials, regulatory approvals, and ability to secure funding and partnerships. Analyst estimates are not readily available.

Recent Initiatives: Recent strategic initiatives would likely include advancing clinical trials for its lead compounds and securing partnerships to fund development and commercialization.

Summary

Scinai Immunotherapeutics Ltd. is a small biopharmaceutical company with a focus on immunotherapy, especially targeting autoimmune diseases. Its strength lies in its novel IL-18BP platform, but it faces challenges with limited financial resources and competition from larger companies. Successful clinical trials and strategic partnerships are essential for its growth. The company must look out for the long and rigorous regulatory path to have a successful and profitable product line.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Websites
  • SEC Filings
  • Industry Reports
  • Financial News Outlets

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a financial advisor. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Scinai Immunotherapeutics Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2015-05-12
CEO & Director Mr. Amir Reichman M.B.A., M.Sc.
Sector Healthcare
Industry Biotechnology
Full time employees 31
Full time employees 31

Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.